The STS and STS Plus Solid Tumor NGS solutions are designed for the analysis of 42 relevant genes associated with the development of the most common solid tumors: lung, colorectal, skin and brain cancer, from DNA extracted from FFPE, fresh or frozen tissue. It also covers 6 unique loci to detect MSI status associated with colorectal cancer.
Both solutions allow accurate detection of SNVs, Indels and CNVs (in 24 genes), and Microsatellite Instability (MSI) status. The STS Plus solution also targets 137 fusion genes.
- High on-target reads percentage
- High coverage uniformity, even in GC-rich regions
- Library preparation in just 6 hours for RNA and 1.5 days for DNA
- Customizable content to meet the needs of each laboratory
STS and STS Plus offer a streamlined sample-to-report workflow, which makes variant assessment quicker and easier, ensuring reliable results.
These NGS solutions include a capture-based target enrichment kit, as well as the functionality and analytical capabilities of the SOPHiA DDM™ platform for data interpretation. Sequencing can be performed on Illumina platforms.
The SOPHiA DDM™ platform features intuitive variant filters and prioritization options to streamline the interpretation process.
- Hotspot Screening to quickly pinpoint the relevant hotspots and provide a clear overview of the wild-type hotspot positions
- Variant Pre-Classification to improve variant pathogenicity assessment
- Virtual panels to limit interpretation to a subset of genes
- Cascading filters to enable user-created custom filtering strategies for quicker identification of relevant variants
- OncoPortal™ to support decisions based on the Jax-CKB™, CAP, ASCO, AMP and other databases
In addition to the STS and STS Plus solutions, other solutions are available for clinical diagnostics in areas such as metabolism, oncology, genetics or cardiology.
